About GondolaBio GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
What You'll Do You will design and execute integrative computational analyses spanning multiomics datasets to accelerate therapeutic discovery in rare and genetically defined diseases. Working independently in a collaborative, data-driven environment, you will identify opportunities where diverse biological data can answer challenging scientific questions, generate therapeutic hypotheses, and advance biomarker discovery.
You will leverage AI-enabled computational approaches to accelerate scientific discovery while applying sound scientific judgment throughout the research process. Responsibilities Design, execute, and interpret integrative computational analyses spanning transcriptomic, proteomic, genetic, and other biological data modalities to support target identification, biomarker discovery, mechanism-of-action studies, and translational research.
Integrate public and internal datasets to generate, prioritize, and refine therapeutic hypotheses across diverse disease programs. Collaborate closely with cross-functional scientists to translate computational analyses into actionable scientific insights. Communicate results clearly and effectively through presentations, written reports, and contributions to scientific publications and conferences. Where You'll Work This is a U.S.-based remote role with periodic travel (quarterly or as needed) to GondolaBio's Palo Alto office or conference locations.
Job details are sourced from the employer's original posting.
Open job postingAbout the company
This company is involved in clinical pharmacology and early clinical development, focusing on early clinical sciences and development strategy from first-in-human through Phase 2. They also lead quantitative sciences including data analytics, pharmacometrics, biostatistics, and data management to inform dose selection and program development.